SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6981)4/14/1998 1:44:00 PM
From: RT  Respond to of 23519
 
<< Exactly 1 patient in the Viagra clinical studies ever discontinued therapy due to vision adverse reaction. >>

BigKNY3

Only one smart patient in the study? I think it's time to invest in some SEEING EYE DOG Stocks.

RT



To: BigKNY3 who wrote (6981)4/14/1998 1:54:00 PM
From: EyeDrMike  Respond to of 23519
 
<<Mike: How does "more frequently" become 40%?>>

Nina said upto 40%, and PFE's own statement says 11% at 100mg and increases with higher dosage.

Amazed that this is your response to the questions i posed.

No backbone to go on record? Never a critical word on PFE? Go back to the PFE board and do the cheerleading if you don't want to have an open discussion here.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News